A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American ophthalmological society thesis)

Transactions of the American Ophthalmological Society

Volumn 104, Issue , 2006, Pages 478-492

  Sherwood, Mark Brian ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; ILOMASTAT; MANNOSE 6 PHOSPHATE; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNULA; CONTROLLED STUDY; DISEASE COURSE; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; GOBLET CELL; HISTOPATHOLOGY; MEDICAL SOCIETY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RABBIT; SCAR FORMATION; SURVIVAL; TREATMENT FAILURE; WOUND HEALING;

ALKYLATING AGENTS; ANIMALS; ANTIMETABOLITES; BLISTER; CONJUNCTIVA; CONNECTIVE TISSUE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FILTERING SURGERY; GLAUCOMA; IMMEDIATE-EARLY PROTEINS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAOCULAR PRESSURE; MALE; MANNOSEPHOSPHATES; MITOMYCIN; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RABBITS; TRANSFORMING GROWTH FACTOR BETA2; TREATMENT FAILURE; WOUND HEALING;

EID: 33947678180     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (191)

1. Roodhooft JM. Leading causes of blindness worldwide. Bull Soc Belge Ophtalmol 2002;283:19-25.
2. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-393.
3. Pizzarello L, Abiose A, Ffytche T, et al. VISION 2020: The Right to Sight: A global initiative to eliminate avoidable blindness. Arch Ophthalmol 2004;122:615-620.
4. Thylefors B, Negrel A. The global impact of glaucoma. Bull World Health Org 1994;72:323-326.
5. Foster A, Johnson G. Magnitude and causes of blindness in the developing world. Int Ophthalmol 1990;14:135-140.
6. Basic and Clinical Sciences Course. Section 10, Glaucoma. San Francisco, California: American Academy of Ophthalmology; 2001-2002.
7. Miller RD, Barber JC. Trabeculectomy in black patients. Ophthalmic Surg 1981;12:46-50.
8. Berson D, Zauberman H, Landau L, et al. Filtering operations in Africans. Am J Ophthalmol 1969;67:395-398.
9. Scott IU, Greenfield DS, Schiffman J, et al. Outcomes of primary trabeculectomy with the use of adjunctive mitomycin. Arch Ophthalmol 1998;116:286-291.
10. Shin DH, Hughes BA, Song MS, et al. Primary glaucoma triple procedure with or without adjunctive mitomycin. Prognostic factors for filtration failure. Ophthalmology 1996;103:1925-1933.
11. Merritt JC. Filtering procedures in American blacks. Ophthalmic Surg 1980;11:91-94.
12. Iliff CE. Surgical control of glaucoma in the negro. Am J Ophthalmol 1944;27:731-738.
13. Polansky JR. Current perspectives on the TIGR/MYOC gene (Myocilin) and glaucoma. Ophthalmol Clin North Am 2003;16:515-527, v-vi.
14. Weisschuh N, Schiefer U. Progress in the genetics of glaucoma. Dev Ophthalmol 2003;37:83-93.
15. Tamm ER. Myocilin and glaucoma: facts and ideas. Prog Retin Eye Res 2002;21:395-428.
16. Vasconcellos JP, Melo MB, Costa VP, et al. Novel mutation in the MYOC gene in primary open glaucoma patients. J Med Genet 2000;37:301-303.
17. Sarfarazi M, Rezaie T. Optineurin in primary open angle glaucoma. Ophthalmol Clin North Am 2003;16:529-541.
18. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol 2004;122:17-21.
19. Medeiros FA, Sample PA, Zangwill LM, et al. Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol 2003;136:805-813.
20. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-720.
21. Palmberg P. Evidence-based target pressures: how to choose and achieve them.Int Ophthalmol Clin 2004;44:1-14.
22. Palmberg P. How clinical trial results are changing our thinking about target pressures. Curr Opin Ophthalmol 2002;13:85-88.
23. Migdal C, Gregory W, Hitchings RA. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651-1657.
24. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-1953.
25. Feiner L, Plitz-Seymour JR. Collaborative Initial Glaucoma Treatment Study: A summary of results to date. Curr Opin Ophthalmol 2003;14:106-111.
26. Jay J. Rational choice of therapy in primary open angle glaucoma. Eye 1992;6:243-247.
27. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-440.
28. Shirakashi M, Iwata K, Sawaguchi S, et al. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica 1993;207:1-5.
29. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
30. Shigeeda T, Tomidokoro A, Araie M, et al. Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology 2002;109:766-770.
31. Wilson MR, Kosoko O, Cowan CL Jr, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002;134:399-405.
32. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol 2003;48 Suppl 1:S3-7.
33. Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126;487-497.
34. Addicks EM, Quigley A, Green WR, et al. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795-798.
35. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983;103:84-88.
36. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48:314-346.
37. Esson DW, Popp MP, Liu L, et al. Microarray analysis of the failure of filtering "blebs" in a rat model of glaucoma filtering surgery. Invest Ophthalmol Vis Sci. 2004;45:4450-4462.
38. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye 2000;14 (Pt 3B):536-547.
39. Chang MR, Cheng Q, Lee DA. Basic science and clinical aspects of wound healing in glaucoma filtering surgery. J Ocul Pharmacol Ther 1998;14:75-95.
40. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987;32:149-170.
41. Grierson I, Joseph J, Miller M, et al. Wound repair: the fibroblast and the inhibition of scar formation. Eye 1988;2 (Pt 2):135-148.
42. Tahery MM, Lee DA. Review: pharmacologic control of wound healing in glaucoma filtration surgery. J Ocul Pharmacol 1989;5:155-179.
43. Skuta GL. Antifibrotic agents in glaucoma filtering surgery. Int Ophthalmol Clin 1993;33:165-182.
44. Rockwood EJ, Parrish RK 2nd, Heuer DK, et al. Glaucoma filtering surgery with 5-fluorouracil. Ophthalmology 1987;94:1071-1078.
45. Akarsu C, Onol M, Hasanreisoglu B. Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up. Clin Exp Ophthalmol 2003;31:199-205.
46. Membrey WL, Poinoosawmy DP, Bunce C, et al. Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 intraocular pressure control and complications. Br J Ophthalmol 2000;84:586-590.
47. Yoon PS, Singh K. Update on antifibrotic use in glaucoma surgery, including use in trabeculectomy and glaucoma drainage implants and combined cataract and glaucoma surgery. Curr Opin Ophthalmol 2004;15:141-146.
48. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-flourouracil. Am J Ophthalmol 1992;114:544-553.
49. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin-C (letter). Arch Ophthalmol 1992;110:1049-1050.
50. Greenfield DS, Liebmann JM, Jee J, et al. Late onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol 1998;16:443-447.
51. Mietz H, Addicks K, Bloch W, et al. Long-term intraocular toxic effects on topical mitomycin-C in rabbits. J Glaucoma 1996;5:325-333.
52. Wolner B, Liebmann JM, Sassani JW, et al. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-flourouracil. Ophthalmology 1991;98:1053-1060.
53. Waheed S, Liebmann JM, Greenfield DS, et al. Recurrent bleb infections. Br J Ophthalmol 1998;82:926-929.
54. Mac I, Soltau JB. Glaucoma-filtering bleb infections. Curr Opin Ophthalmol 2003;14:91-94.
55. Belyea DA, Dan JA, Stamper RL, et al. Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorouracil and mitomycin C. Am J Ophthalmol 1997;124:40-45.
56. Parrish R, Minckler D. Late endophthalmitis: filtering surgery time-bomb? Ophthalmology 1996;103:1167-1168.
57. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology 1996;103:650-656.
58. Jampel HD, Quigley HA, Kerrigan-Baumrind LA, et al. Glaucoma surgical outcomes study group. Risk factors for late-onset infection following glaucoma filtration surgery. Arch Ophthalmol 2001;119:1001-1008.
59. Mietz H, Jacobi PC, Krieglstein GK. Postoperative application of mitomycin for trabeculectomies. Arch Ophthalmol 2000;118:1341-1348.
60. Kangas TA, Greenfield DS, Flynn HW, et al. Delayed onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology 1997;104:746-752.
61. Soltau JB, Rothman RF, Bidenz DL, et al. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol 2000;118:338-342.
62. Cordeiro MF, Mead A, Ali RR, et al. Novel antisense oligonucleotides targeting TGF-beta inhibit in-vivo scarring and improve surgical outcome. Gene Ther 2003;10:59-71.
63. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 1999;40:2225-2234.
64. Esson DW, Neelakantan A, Iyer SA, et al. Expression of connective tissue growth factor after glaucoma filtration surgery in a rabbit model. Invest Ophthalmol Vis Sci 2004;45:485-491.
65. Cordeiro MF, Balasubramanian L, Ali RR, et al. Effect and localization of a TGF-β1 antisense oligonucleotide in conjunctival scarring - a potential new anti-scarring strategy in glaucoma surgery [abstract]. Invest Ophthalmol Vis Sci 2000;41:S744.
66. Siriwardena D, Khaw PT, King AJ, et al. Hyman anti-transforming growth factor beta(2) monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 2002;109:427-431.
67. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002;4:599-604.
68. Kothapalli D, Frazier KS, Welply A, et al. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor dependent signaling pathway. Cell Growth Differ 1997;8:61-68.
69. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 2002;21:473-82.
70. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
71. Mauch C, Krieg T, Bauer EA. Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res 1994;287:107-114.
72. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulate fibroblast-mediated matrix contraction and collagen production in-vitro. Invest Ophthalmol Vis Sci 2003;44:1104-1110.
73. Scott KA, Wood EJ, Karran EH. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett 1998;441:137-140.
74. Sheridan CM, Occleston NL, Hiscott P, et al. Matrix metalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am J Pathol 2001;159:1555-1566.
75. Pelton RW, Hogan BL, Miller DA, Moses HL. Differential expression of genes encoding TGFs beta 1, beta 2, and beta 3 during murine palate formation. Dev Biol 1990;141:456-460.
76. Chang L, Crowston JG, Cordeiro MF, et al. The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv Ophthalmol 2000;45:49-68
77. Khaw PT, Chang L, Wong TT, et al. Modulation of wound healing after glaucoma surgery. Curr Opin Ophthalmol 2001;12:143-8 [erratum in: Curr Opin Ophthalmol 2001;12:235].
78. Cordeiro MF, Siriwardena D, Chang L, Khaw PT. Wound healing modulation after glaucoma surgery. Curr Opin Ophthalmol 2000;11:121-126.
79. Atreides SP, Skuta GL, Reynolds AC. Wound healing modulation in glaucoma filtering surgery. Int Ophthalmol Clin 2004;44:61-106.
80. Costa VP, Spaeth GL, Eiferman RA, Orengo-Nania S. Wound healing modulation in glaucoma filtration surgery. Ophthalmic Surg 1993;24:152-170.
81. Jampel HD. Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon's capsule fibroblasts. Ophthalmology 1992;99:1471-1476.
82. Khaw PT, Sherwood MB, MacKay SL, et al. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have longterm effects on human Tenon's capsule fibroblasts. Arch Ophthalmol 1992;110:1150-1154.
83. Uchio K, Graham M, Dean NM, et al. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen. 2004;12:60-66.
84. Moussad EE, Brigstock DR. Connective tissue growth factor: What's in a name? Mol Genet Metab 2000;71:276-292.
85. Galardy RE, Cassabonne ME, Giese C, et al. Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci 1994;732:315-323.
86. Levy DE, Lapierre F, Liang W, et al. Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem 1998;41:199-223.
87. Daniels JT, Schultz GS, Blalock TD, et al. Medication of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring. Am J Pathol 2003;163:2043-2052.
88. Wong TT, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates post-operative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2003;44:1097-1103.
89. Clark R, Henson P. The Molecular and Cellular Biology of Wound Repair. New York: Plenum Press; 1988.
90. Witte MB, Barbul A. General principles of wound healing. Surg Clin North Am 1997;77:509-528.
91. Singer A, Clark R. Cutaneous wound healing. N Engl J Med 1999;341:738-746.
92. Desjardins DC, Parrish RK II, Folberg R, et al. Wound healing after filtering surgery in owl monkeys. Arch Ophthalmol 1986;104:1835-1839.
93. Desjardins DC, Parrish RK II, Folberg R, et al. Wound healing after filtering surgery in owl monkeys. Arch Ophthalmol 1986;104:1835-1839.
94. Dvorak HF. Tumors: wounds that do not heal; similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659.
95. Albert DM, Jakobiec FA. New surgical techniques in glaucoma management. In: Principles and Practice of Ophthalmology. 2nd ed. Philadelphia: WB Saunders;2000;3024-3030.
96. Seetner A, Morin JD. Healing of trabeculectomies in rabbits. Can J Ophthalmol 1979;14:121-125.
97. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye 2000;14:536-547.
98. Cordeiro M, Reichel M, Gay J, et al. TGF-1, -2 and -3 in vivo: effects on normal and mitomycin-C modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999;1975-1982.
99. Cordeiro M, Bhattacharya S, Schultz G, Khaw PT. TGF-beta1, -beta2 and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation and migration. Invest Ophthalmol Vis Sci 2000;41:756-763.
100. Connor T, Roberts A, Sporn M, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989;83:1661-1666.
101. Jampel H, Roche N, Stark W, et al. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963-969.
102. Miller MH, Grierson I, Unger WI, Hitchings RA. Wound healing in an animal model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg 1989;20:350-357.
103. Reichel MB, Cordeiro MF, Alexander RA, Cree IA, et al. New model of conjunctival scarring in the mouse eye. Br J Ophthalmol 1998;82:1072-1077.
104. Jampel HD, McGuigan LJ, Dunkelberger GR. Cellular proliferation after experimental glaucoma filtering surgery. Arch Ophthalmol 1988;106:89-94.
105. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996;121:349-366.
106. Heuer DK, Parrish RK II, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery: II. A pilot study. Ophthalmology 1984;91:384-393.
107. Heuer DK, Parrish RK II, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery: III. Intermediate follow-up of a pilot study. Ophthalmology 1986;93:1537-1546.
108. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow-up. Ophthalmology 2000;107:1184-1190.
109. Goldenfeld M, Krupin T, Ruderman JM, et al. 5-Fluorouracil in initial trabeculectomy: a prospective, randomized, multi-center study. Ophthalmology 1994;101:1024-1029.
110. Ruderman JM, Welch DB, Smith MF, et al. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol 1987;104:218-224.
111. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993;4:637-645.
112. Beckers HJ, Kinders KC, Webers CA. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol 2003;241:106-110.
113. Cheung JC, Wright MM, Murali S, et al. Intermediate-term outcome of variable dose mitomycin C filtering surgery. Ophthalmology 1997;104:143-149.
114. Perkins TW, Gangnon R, Ladd W, et al. Trabeculectomy with mitomycin C: intermediate-term results. J Glaucoma 1998;7:230-236.
115. Bindlish R, Condon GP, Schlosser JD, et al. Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up. Ophthalmology 2002;109:1336-1341.
116. Gonzalez Vela JL, Sanchez Guillen JM, Trevino Aguirre SA, et al. Efectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer. Clin Transl Oncol 2005;7:441-446.
117. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005;45:983-991.
118. Youdim MB, Buccafusco JJ. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm 2005;112:519-537.
119. Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005;26:27-35.
120. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004;3:1001-1010.
121. Litz J, Sakuntala Warshamana-Greene G, Sulanke G, et al. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 2004;46:283-291.
122. Leese MP, Newman SP, Purohit A, et al. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted antitumour agents. Bioorg Med Chem Lett. 2004;14:3135-3138.
123. Borkow G, Lapidot A. Multi-targeting the entrance door to block HIV-1. Curr Drug Targets Infect Disord. 2005;5:3-15.
124. Latham V, Stebbing J, Mandalia S, et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother 2005;56:186-189.
125. Starita RJ, Fellman RL, Spaeth GL, et al. Short- and long-term effects of postoperative corticosteroids on trabeculectomy. Ophthalmology 1985;92:938-946.
126. Araujo SV, Spaeth GL, Roth SM, Starita RJ. A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology 1995;102:1753-1759.
127. Parrillo JE, Fauci AS. Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 1979;19:179-201.
128. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982;65:133-155.
129. Oshima T, Kurosaka D, Kato K, et al. Tranilast inhibits cell proliferation and collagen synthesis by rabbit corneal and Tenon's capsule fibroblasts. Curr Eye Res 2000;20:283-286.
130. Chihara E, Dong J, Ochiai H, et al. Effects of tranilast on filtering blebs: a pilot study. J Glaucoma 2002;11:127-133.
131. Akman A, Bilezikci B, Kucukerdonmez C, et al. Suramin modulates wound healing of rabbit conjunctiva after trabeculectomy: comparison with mitomycin C. Curr Eye Res 2003;26:37-43.
132. Mietz H, Chevez-Barrios P, Feldman RM, et al. Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmol 1998;82:816-820.
133. Mietz H, Krieglstein GK. Suramin to enhance glaucoma filtering procedures: a clinical comparison with mitomycin. Ophthalmic Surg Lasers 2001;32:358-369.
134. Gillies MC, Brooks AM, Young S, et al. A randomized phase II trial of interferon alpha2b versus 5-fluorouracil after trabeculectomy. Aust N Z J Ophthalmol 1999;27: 37-44.
135. Cristofanilli M, Pescosolido N, Risuleo G, et al. A murine cell culture model for post-trabeculectomy anfibrotic treatment: induction of apoptosis by cyclosporine. Acta Ophthalmol Scand 2001;79:309-312.
136. Nuzzi R, Cerruti A, Finazzo C. Cyclosporine C: a study of wound-healing modulation after trabeculectomy in rabbit. Acta Ophthalmol Scand Suppl 1998;227:48-49.
137. Turacli ME, Gunduz K, Aktan G, et al. Topical cyclosporine as a possible new antimetabolite in trabeculectomy. Ophthalmic Surg Lasers 1996;27:438-444.
138. Turacli E, Gunduz K, Aktan G, et al. A comparative clinical trial of mitomycin C and cyclosporine A in trabeculectomy. Eur J Ophthalmol 1996;6:398-401.
139. Grisanti S, Szurman P, Warga M, et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 2005;46:191-196.
140. Mietz H, Chevez-Barrios P, Lieberman MW, et al. Decorin and suramin inhibit ocular fibroblast collagen production. Graefes Arch Clin Exp Ophthalmol 1997;235:399-403.
141. Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma sugery. Invest Ophthalmol Vis Sci 2003;44:3394-3401.
142. Blakytny R, Ludlow A, Martin GE, et al. Latent TGF beta-1 activation by platelets. J Cell Physiol 2004;1991:67-76.
143. Khalil N. TGF beta: from latent to active. Microbes Infect 1999;1:1255-1263.
144. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A 1991;88:580-584.
145. Weiner JA, Chen A, Davis BH. Platelet-derived growth factor is a principal inductive factor modulating mannose 6-phosphate/insulin-like growth factor-II receptor gene expression via a distal E-box in activated hepatic stellate cells. Biochem J 2000;345 Pt 2:225-231.
146. Ghahary A, Tredget EE, Shen Q. Insulin-like growth factor II/mannose-6 phosphate receptors facilitate the matrix effects of latent transforming growth factor β1 released from genetically modified keratinocytes in a fibroblast/keratinocyte coculture system. J Cell Physiol 1999;180:61-70.
147. Ghahary A, Tredget EE, Shen Q, et al. Mannose 6 phosphate/IGF-II receptors mediate the effects of IGF-1 induced latent transforming growth factor beta 1 on expression of type 1 collagen and collagenase in dermal fibroblasts. Growth Factors 2000;17:167-176.
148. Cordeiro MF. Beyond mitomycin: TGF-beta and wound healing. Prog Retin Eye Res 2002;21:75-89.
149. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye 2000;14(Pt 3B):536-547.
150. Cordeiro MF. Technology evaluation: lerdelimumab, Cambridge Antibody Technology. Curr Opin Mol Ther 2003;5:199-203.
151. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 1999;40:2225-2234.
152. Siriwardena D, Khaw PT, Donaldson ML, et al. A randomised placebo controlled trial of human anti-TGFβ2 monoclonal antibody (CAT-152): a new modulator of wound healing following trabeculectomy [abstract]. Invest Ophthalmol Vis Sci 2000;41:S744.
153. R phase II/III clinical trial. (Press release) Cambridge, England: Cambridge Antibody Technology, November 9, 2004.
154. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down regulation by camp. FASEB J 1999;13:1774-1786.
155. Ihn H. Pathogenesis of fibrosis: role of TGF-beta abd CTGF. Curr Opin Rheumatol 2002;14:681-685.
156. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 2003;11;278:13008-13015.
157. Daniels JT, Schultz GS, Blalock TD, et al. Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring. Am J Pathol 2003;163:2043-2052.
158. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002;4:136-142.
159. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003;81:355-363.
160. Parekh T, Saxena B, Reibman J, et al. Neutrophil chemotaxis in response to TGF-beta isoforms (TGF-beta 1, TGF-beta 2, TGFbeta-3) is mediated by fibronectin. J Immunol 1994;152:2456-2466.
161. Pena RA, Jerdan JA, Glaser BM. Effects of TGF-beta and TGF-beta neutralizing antibodies on fibroblast-induced collagen gel contraction: implications for proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994;35:2804-2808.
162. Frazier K, Williams S, Kothapalli D, et al. Stimulation of fibroblast cell growth, matrix production and granulation of tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107:404-411.
163. Blalock TD, Duncan MR, Varela JC, et al. Connective tissue growth factor expression and action in human corneal fibrolast cultures and rat corneas after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2003;1879-1887.
164. Berry DP, Harding KG, Stanton MR, et al. Human wound contraction: collagen organization, fibroblasts, and myofibroblasts. Plast Reconstr Surg 1998;102:124-131.
165. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibrolast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci 2003;44:1104-1110.
166. Ravanti L, Kahari V-M. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000;6:391-407.
167. Wong TTL, Sethi C, Daniels JT, et al. Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol 2002;47:239-256.
168. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 2002;21:1-14.
169. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-464.
170. Steffensen B, Hakkinen L, Larjava H. Proteolytic events of wound-healing-coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol Med 2001;12:373-398.
171. St-Pierre Y, Van Themsche C, Esteve PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy 2003;2:206-215.
172. Van den Steen PE, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536.
173. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling as well as pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;28:12-24.
174. Mietz H, Esser JM, Welsandt G, et al. Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci 2003;44:5182-5188.
175. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253:269-285.
176. Galardy RE, Cassabonne ME, Giese C, et al. Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci 1994;732:315-323.
177. Wong TT, Mead AL, Khaw PT. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2005;46:2018-2022.
178. Purchio AF, Cooper JA, Brunner AM, et al. Identification of mannose 6-phosphate in two asparagine-linked sugar chains of recombinant transforming growth factor-beta 1 precursor. J Biol Chem 1988;263:14211-14215.
179. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci 1991;88:580-584.
180. DeBleser PJ, Jannes P, Van Buul-Offers SC, et al. Insulin like growth factor-II/mannose 6-phosphate receptor is expressed on CC14-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells. Hepatology 1995;21:1429-1437.
181. Cunliffe IA, Richardson PS, Rees RC, Rennie IG. Effect of TNF, IL-1, and IL-6 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Br J Ophthalmol 1995;79:590-595.
182. Denk PO, Roth-Eichhorn S, Gressner AM, Knorr M. Effect of cytokines on regulation of the production of transforming growth factor beta-1 in cultured human Tenon's capsule fibroblasts. Eur J Ophthalmol 2000;10:110-115.
183. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res 2004;79:677-688.
184. Chang L, Siriwardena D, Wilkins MR, et al. In vivo production of interferon beta by human Tenon's fibroblasts; a possible mediator for the development of chronic conjunctival inflammation. Br J Ophthalmol 2002;86:611-615.
185. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci 2000;41:756-763.
186. Tripathi RC, Li J, Chalam KV, Tripathi BJ. Expression of growth factor mRNAs by human Tenon's capsule fibroblasts. Exp Eye Res 1996;63:339-346.
187. Ellis DG, Cheng Q, Lee DA. The effects of growth factors on Tenon's capsule fibroblasts in serum-free culture. Curr Eye Res 1996;15:27-35.
188. Gillies MC, Su T. Cytokines, fibrosis and the failure of glaucoma filtration surgery. Aust N Z J Ophthalmol 1991;19:299-304.
189. Denk PO, Hoppe J, Hoppe V, Knorr M. Effect of growth factors on the activation of human Tenon's capsule fibroblasts. Curr Eye Res 2003;27:35-44.
190. Wong TT, Mead AL, Khaw PT. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2005;46:2018-2022.
191. Liu CJ, Huang YL, Chiu AW, Ju JP. Transcript expression of matrix metalloproteinases in the conjunctiva following glaucoma filtration surgery in rabbits. Ophthalmic Res 2004;36:114-119.